7 Penny Stocks to Buy in July 2022 | investorplace.com • |
Bet on 5 Top Stocks With Rising P/E | zacks.com • |
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis | wsj.com • |
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid | zacks.com • |
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy | investorplace.com • |
Clovis Oncology stock slides 10% premarket after company files for bankruptcy | marketwatch.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-11-09 | 2022-09 | -0.42 | N/A | N/A | N/A |
2022-08-08 | 2022-06 | -0.42 | N/A | N/A | N/A |
2022-05-04 | 2022-03 | -0.43 | N/A | N/A | N/A |
2022-02-23 | 2021-12 | -0.6 | N/A | N/A | N/A |
2021-11-03 | 2021-09 | -0.48 | N/A | N/A | N/A |
2021-08-04 | 2021-06 | -0.57 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-11-10 | JP Morgan | Downgrade | Neutral | Underweight |
2022-05-06 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2022-05-05 | HC Wainwright & Co. | Upgrade | Buy | |
2021-09-21 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-05 | HC Wainwright & Co. | Upgrade | Buy | |
2021-05-05 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-11-01 | GROSS PAUL EDWARD | General Counsel | 98.33K | Sale |
2022-11-01 | HARDING THOMAS C | Officer | 0.00 | Sale |
2022-11-01 | IVERS-READ GILLIAN C | Officer | 293.61K | Sale |
2022-11-01 | MUEHL DANIEL W | Chief Financial Officer | 104.83K | Sale |
2022-11-01 | ROLFE LINDSEY | Officer | 113.69K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-09-29 | Vanguard Group, Inc. (The) | 10.21M | 828.77K | 7.04% |
2022-09-29 | Palo Alto Investors Lp | 4.47M | 363.29K | 3.09% |
2022-09-29 | Blackrock Inc. | 4.04M | 327.67K | 2.78% |
2022-09-29 | QVT Financial LP | 3.53M | 286.23K | 2.43% |
2022-09-29 | Renaissance Technologies, LLC | 2.21M | 179.43K | 1.52% |
2022-09-29 | Geode Capital Management, LLC | 1.38M | 112.30K | 0.95% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-09-29 | Vanguard Total Stock Market Index Fund | 4.34M | 352.67K | 3.00% |
2022-09-29 | Vanguard Extended Market Index Fund | 1.92M | 155.70K | 1.32% |
2022-09-29 | Vanguard Strategic Equity Fund | 1.68M | 136.34K | 1.16% |
2022-07-30 | Vanguard Explorer Fund, Inc. | 1.44M | 116.87K | 0.99% |
2022-11-29 | iShares NASDAQ Biotechnology ETF | 1.17M | 94.72K | 0.80% |
2022-10-30 | Fidelity Extended Market Index Fund | 747.38K | 60.69K | 0.52% |
-
$SMART$9X. I Believe it!!
-
Keep Going!! Hurry Up Clovis.
Perfect!!
-
Good sign the climb of Clovis. $0.90. When you agree or exploit all the excellent news, this is going to get well up on the SHARE.
Only Half noise!!
Jejeje!! It’s a good chat.
Big greeting.
-
Tomorrow Earnings BMY.
Do you think that’s excellent for CLOVIS? #CLVS#.
What is your expectation?
-
Excellent $MART9$#.
Enjoy!!
Up 10.5 last 30 minutes.
-
It's getting beautiful!!!
Hurry Up!! CLOVIS
CLVS 10.50$
-
Come on Baby!! Hurry up. $CVLS$. 10,5
-
10.20 Keep Going!! #CLVS$$.
Yesssss!!!
-
My prediction for TODAY 10.20$. clVS. I said you yesterday 6pm. Bravoooo
-
Right Now!!! CLVS 8.88$.
Prediction for tomorrow 10.20
-
Take -Off last time. Something is coming. Soon #CLVS#.
-
8.90$ Close Today. Sure
-
Triple 8.88$$$
-
Something NEW is Cooking. #CLVS#.
-
Let’s Gooooooo!!!!
-
A big question? Because they ignored the approval yesterday by FRANCE (sDNA-Rubracca) and his acquisition in the sector. How big news in NYSE. This is an extraordinary information for CLlVS and there's no reaction.....
-
With all this news. Draw your conclusions.
##$$CLVS##$$Enjoy.
Greetings.
-
TODAY IN FRANCE.
Clovis Oncology Announces Availability And Reimbursement For Rubraca (Rucaparib) Tablets For Women With Relapsed Ovarian Cancer In France
- Rubraca (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type
- Rucaparib provided statistically significant improvement in progression-free survival (PFS) versus placebo in all ovarian cancer patients studied1
- Some patients with residual disease at ARIEL3 study entry who were treated with rucaparib showed further reduction in tumor burden, including complete responses1
- Most common Grade ≥3 adverse reaction was anemia; the only serious adverse reaction occurring in >2 percent of patients was anemia2
- Rucaparib now available in multiple countries across Europe.
-
Patrick J Mahaffy, Clovis Oncology's President and CEO and a director of the company, just received 250,000 options from the company. The strike price of the options received was $8.39, and these expire on February 03, 2030. Mahaffy now owns at least 250,000 options on the company.
Some additional info was provided as follows:
The option shall vest as to 25% of the shares on January 31, 2021, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The option shall vest upon the submission by the Company to the FDA of an IND for FAP-2286 on or before December 31, 2020.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Clovis Oncology makes a similar move, sign up!
Other recent filings from the company include the following:
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020 -
Patrick J Mahaffy, Clovis Oncology's President and CEO and a director of the company, just received 250,000 options from the company. The strike price of the options received was $8.39, and these expire on February 03, 2030. Mahaffy now owns at least 250,000 options on the company.
Some additional info was provided as follows:
The option shall vest as to 25% of the shares on January 31, 2021, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The option shall vest upon the submission by the Company to the FDA of an IND for FAP-2286 on or before December 31, 2020.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Clovis Oncology makes a similar move, sign up!
Other recent filings from the company include the following:
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
Clovis Oncology's See Remarks was just granted 74,000 restricted shares - Jan. 31, 2020
-
7 Penny Stocks to Buy in July 2022
investorplace.com • -
Bet on 5 Top Stocks With Rising P/E
zacks.com • -
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy
investorplace.com • -
Dear CLVS Stock Fans, Get Ready for a Bankruptcy Filing
investorplace.com • -
7 Stocks to Sell Right Now
investorplace.com • -
Best Penny Stocks To Buy? 7 To Watch Under $1 Right Now
pennystocks.com • -
Clovis Oncology (CLVS) Stock Pops After Bankruptcy Warning
investorplace.com • -
Why Is Clovis Oncology (CLVS) Stock Down 72% Today?
investorplace.com •